



AGENDA

New York
Cardiovascular
Symposium



FRIDAY, DECEMBER 7

6:00 a.m. Continental Breakfast

Introductions

7:15 a.m. **Tim Attebery, MBA**
Chief Executive Officer
American College of Cardiology

C. Michael Valentine, MD, FACC
President
American College of Cardiology

J. Chad Teeters, MD, FACC
President, New York State Chapter
American College of Cardiology

Cardiovascular and Coronary Artery Disease – Challenges in 2018

Session I: New Frontiers

Dr. Bhatt, Presiding

7:30 a.m.	Noninvasive Approach to Subclinical Arterial Disease in 12,000 Subjects Burden of Disease has Prognostic Value thru Imaging and Omics	<i>Dr. Fuster</i>
8:00 a.m.	Invasive Approach to Clinical Arterial Disease in 3,000 Patients Vulnerable Plaques don't have Prognostic Value, Except Value thru Research	<i>Dr. Zadeh</i>
8:25 a.m.	Noninvasive Approach to Inflammation in Coronary Artery Disease Therapeutic Blockade of Innate Immunity	<i>Dr. Ridker</i>
8:50 a.m.	Panel Discussion	<i>Drs. Fuster, Zadeh and Ridker</i>
9:20 a.m.	Coffee Break	

Session II: Acute Coronary Syndromes

Dr. Bhatt, Presiding

9:40 a.m.	STEMI 1: PCI of Culprit Lesion Alone vs FFR Guided Complete Revascularization Effects on Hard End Points, MACE and Cost Effectiveness	<i>Dr. Bhatt</i>
10:05 a.m.	STEMI 2: Cardiogenic Shock and Revascularization Strategies; Seeking Benefit with Mechanical Support, PCI and CABG	<i>Dr. Hochman</i>
10:30 a.m.	STEMI vs NSTEMI vs STABLE CAD – Post PCI Optimal DAPT Approaches Scoring Type of Stent, Complexity of Disease and Thrombosis vs Bleeding	<i>Dr. Bhatt</i>
10:55 a.m.	STEMI vs NSTEMI vs STABLE CAD – Five Challenging Cases Five Challenging Antithrombotic Approaches	<i>Dr. Angiolillo</i>
11:20 a.m.	Panel Discussion	<i>Drs. Bhatt, Hochman and Angiolillo</i>
Noon	Lunch	

Session III: Systemic Arterial Disease – Chronic Coronary Disease, Stroke and Pulmonary Embolism

Dr. O'Gara, Presiding

1:00 p.m.	Chest Pain Evaluation: Possible vs. Probable CAD No Test vs Stress Test vs CT Angio	<i>Dr. Bax</i>
1:20 p.m.	Complex Stable CAD – Evolving Managements Anatomy (SYNTAX), Ischemic (FFR, iFR) & Microcirculation (PET,CT, MR)	<i>Dr. Fuster</i>
1:45 p.m.	Acute Ischemic Stroke and Chronic Carotid Artery Stenosis Two Entities with Novelty Approaches	<i>Dr. Hopkins</i>



AGENDA

New York
Cardiovascular
Symposium



2:05 p.m.	Pulmonary Emboli: Diagnosis Based on Suspicion Management Based on the Acute Severity and Degree of Chronic PH	<i>Dr. Goldhaber</i>
2:25 p.m.	Panel Discussion	<i>Drs. Bax, Fuster, Hopkins and Goldhaber</i>
2:55 p.m.	Coffee Break	
Session IV: Trends and Challenges of Approaching Prevention – Health Factors		<i>Dr. Bonow, Presiding</i>
3:15 p.m.	JACC Seminar: Four Challenges to Enhance Eight Health Factors 1. Pathophysiological Effects 2. Mechanistic/Triggering Factors 3. Role of Preventive Action 4. Competencies for Training	<i>Dr. Fuster</i>
3:30 p.m.	1. Nutrition and Diet	<i>Dr. Hu</i>
3:45 p.m.	2. Healthy Weight	<i>Dr. Lavie</i>
4:00 p.m.	3. Physical Activity	<i>Dr. Lavie</i>
4:15 p.m.	4. Tobacco Free	<i>Dr. Rigotti</i>
4:30 p.m.	5. Blood Pressure	<i>Dr. Muntner</i>
4:45 p.m.	6. Cholesterol	<i>Dr. Catapano</i>
5:00 p.m.	7. Blood Sugar	<i>Dr. Ali</i>
5:15 p.m.	8. Psychological Health	<i>Dr. Labarthe</i>
5:30 p.m.	Panel Discussion	<i>Drs. Fuster, Hu, Lavie, Rigotti, Muntner, Catapano, Ali and Labarthe</i>
6:00 p.m.	Adjournment	

SATURDAY, DECEMBER 8

6:15 a.m.	Continental Breakfast	
Cardio-Pulmonary and Electrical Failure 2018		
Session V: Systolic Heart Failure and Basis for Management		<i>Dr. O'Connor, Presiding</i>
7:00 a.m.	Evolving Imaging (MRI, PET) as Diagnostic & Prognostic Tools For 7 Cardiomyopathies – Myocarditis, Dilated CM, Hypertrophic CM, Noncompaction LV, Amyloid CM, Sarcoid & Takotsubo	<i>Dr. Bonow</i>
7:25 a.m.	Evolving Clinical Genetics & Omics in Myocardial Disease Which or What Subgroup of the 7 Entities Should be Gene Tested	<i>Dr. Mann</i>
7:50 a.m.	Evolving Understanding of Heart Failure and Preserve Ejection Function Different Biological Phenotypes and Evolving Therapeutic Options	<i>Dr. Miller</i>
8:20 a.m.	Evolving Therapeutic Approaches to 3 Challenging Cardiomyopathies: Myocarditis, Takotsubo, AL/TTR Amyloid and Non-Compaction LV	<i>Dr. Dec</i>
8:45 a.m.	LVADs – The 3 Upcoming Challenges 1. Indications: Not too Late, Not too Early, Since Risks are High 2. New Biocompatible Devices: Equal Transplant Survival of 10 Years 3. Device Explanation: How to Approach such a Dream	<i>Dr. O'Connor</i>
9:10 a.m.	Panel Discussion	<i>Drs. Bonow, Mann, Miller, Dec and O'Connor</i>



AGENDA

New York
Cardiovascular
Symposium



9:40 a.m.	Coffee Break	
Session VI: Rhythm Disorders, Contemporary and Future Topics of Focus		<i>Dr. Reddy, Presiding</i>
10:00 a.m.	Atrial Fibrillation 2018 – The 14 Non Ablation Clinical Challenges Quality of Life & Preventing Stroke	<i>Dr. Fuster</i>
10:25 a.m.	Atrial Fibrillation: Catheter Ablation – 4 Questions Who?, When?, How?, Results of CAVANA.	<i>Dr. Wilber</i>
10:50 a.m.	Left Atrial Appendage Closure – 4 Questions Who?, When?, How?, Results?	<i>Dr. Reddy</i>
11:15 a.m.	Ventricular Tachycardia: Catheter Ablation – 4 Questions Who?, When ?, How?, Results?	<i>Dr. Marchlinski</i>
11:40 a.m.	Follow up of the 3 recent Device Therapeutic Approaches CRTs Strict Indications, Subcutaneous ICDs, Leadless Pacemakers	<i>Dr. Gold</i>
Noon	Panel Discussion	<i>Drs. Fuster, Wilber, Reddy, Marchlinski and Gold</i>
12:30 p.m.	Lunch	
Session VII: Valvular Heart Disease and Aorta – Challenges in 2018 Management of Aortic Valve Disease and Aorta		<i>Dr. Nishimura, Presiding</i>
1:30 p.m.	Aortic Valvular Stenosis: 4 Challenging Variables for Management Asymptomatic, Known Cardiomyopathy (i.e. Amyloid), Massive LVH Low Flow/Low Gradient	<i>Dr. Bonow Discussant, Dr. Sharma</i>
1:50 p.m.	Severe Aortic Valvular Stenosis – TVAR in 4 Ages and 4 Etiologies Age 25y Congenital, 50y Bicuspid, 75y Rheumatic, 100y Degenerative	<i>Dr. O’Gara Discussant, Dr. Adams</i>
2:10 p.m.	Asymptomatic Severe Aortic Regurgitation & Normal EF The Dilated LV as a Key for Surgical Intervention	<i>Dr. O’Gara Discussant, Dr. Bonow</i>
2:30 p.m.	The Dilated Thoracic & Abdominal Aorta and Complicating Dissection Evolving Understanding of the Basic Biology & Management	<i>Dr. Fuster Discussant, Dr. Adams</i>
3:00 p.m.	Panel Discussion	<i>Drs. Bonow, Sharma, O’Gara, Adams, Fuster, and Nishimura</i>
3:20 p.m.	Coffee Break	
Session VIII: Management of Mitral Regurgitation, Tricuspid Regurgitation and Hypertrophic Cardiomyopathy		<i>Dr. Adams, Presiding</i>
3:40 p.m.	Significant Mitral Regurgitation (Low EF, LVEdD, PH or AF) 2 Etiologies (1ary, 2ary), 3 Approaches (Medical, T. Clipping, Surgical)	<i>Dr. Adams Discussant, Dr. Sharma</i>
4:05 p.m.	Significant Tricuspid Regurgitation (2ary, 1ary), 3 Approaches (Medical, T. Coaptation or Suturing, Surgical)	<i>Dr. Nishimura Discussant, Dr. Adams</i>
4:30 p.m.	Hypertrophic Cardiomyopathy – 4 Challenging Questions Genetics/Acquired, Myectomy/3Types, Natural Hx/ICD, Apical Aneurysm	<i>Dr. Nishimura</i>
4:55 p.m.	Panel Discussion	<i>Drs. Adams, Sharma and Nishimura</i>
5:30 p.m.	Adjournment	



AGENDA

New York
Cardiovascular
Symposium



SUNDAY, DECEMBER 9

6:30 a.m. Continental Breakfast

Year in Review: The Nine Highlights of Progress In 2018

Session IX: Novelties on Genetics, Molecular Signaling and Cell Regeneration

Dr. Fuster, Presiding

7:30 a.m. Part 1: Progress in Precision Medicine: Merger of Genome Editing and Induced Pluripotent Stem Cells to Decipher CVD

Dr. Wu

7:55 a.m. Part 2: Progress in Molecular Cardiovascular Medicine – MicroRNAs and Metabolomics
A New Understanding of Cardiovascular Physiology, Pathology and Future Therapies

Dr. Mayr

8:20 a.m. Part 3: Progress in Myocardial Regeneration – Exosomes and iPCs
A New Understanding of Cardiovascular Physiology, Pathology and Future Therapies

Dr. Bolli

Section X: Novelties on Diagnostic and Therapeutic Strategies

8:45 a.m. Part 1: Tailor-made Decision Making for Surgical or Percutaneous Revascularization Based on Non-invasive Imaging and Comorbidities

Dr. Serruys

9:10 a.m. Part 2: NIH – Hybrid Revascularization in Multi-Vessel Coronary Disease
LIMA – to LAD + PCI of non-LAD vs PCI of all Diseased Vessels

Dr. Puskas

9:35 a.m. Part 3: Cardiac and Renal Effects of SGLT-2 Inhibitors in Diabetes
A New Strategic Possibility for the Treatment of Heart Failure

Dr. Braunwald

10:00 a.m. Coffee Break

Section XI: Aiming at the Future of Medicine

10:20 a.m. Part 1: The Future of Health Education Starting at Pre-School
Results in 4,000 Children, at Short, Middle and Long Term

Dr. Fuster

10:45 a.m. Part 2: The Future of Children Operated for Congenital Heart Disease
Evolving of Heart Teams Integrated by Pediatric & Adult Cardiologists

Dr. Warnes

11:15 a.m. PAUL DUDLEY WHITE LECTURE 2018

Dr. Carpentier

11:45 a.m. Course Adjournment

“ The course was excellent. There was a good mixture of basic and clinical science. ”

– 2017 Attendee